产品展示更多>>
- Diflunisal 22494-42-4
- Diflunisal 22494-42-4
Diflunisal 22494-42-4
产品描述 描述 Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis. .
纯度 ＞98%储存/保存方法 Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.基本信息 别名 二氟ni柳；二氟苯水杨酸；MK-647外观 白色粉末可溶性/溶解性 DMSO : 50 mg/mL (199.84 mM; Need ultrasonic)
Ethanol : 20 mg/mL (79.94 mM)生物活性 靶点 COX ,p300In vitro(体外研究) Diflunisal, an FDA-approved drug containing a salicylic acid substructure, inhibited CBP/p300 more potently than salicylate. Diflunisal exhibits anti-tumor activity against a specific leukemia carrying a t(8;21) translocation, a tumor previously reported to be dependent on p300 in vitro and in vivo.In vivo(体内研究) Diflunisal-mediated kinetic stabilization of TTR(Rate-limiting transthyretin) should ameliorate TTR amyloidoses, provided that the nonsteroidal anti-inflammatory drug liabilities can be managed clinically.参考文献 参考文献 1. Jeske AH. J Gt Houst Dent Soc. 1999, 71(4):39-40.
2. Mao H, et al. J Am Chem Soc. 2001, 123(43):10429-35.
3. Moore PA, Hersh EV. J Am Dent Assoc. 2001, 132(4):451-6.
研究领域 研究领域 ImmunologyCancerTumor biomarkersCancerTumor immunologyDrug DiscoverySmall Molecule DrugLead Compound DiscoveryDiflunisal 22494-42-4温馨提示：本产品仅作科研实验使用，不支持临床等研究